World's Best Scientists 2026 revealed!
Sonja Zweegman

Sonja Zweegman

D-Index & Metrics

Medicine

D-Index
91
Citations
35698
World Ranking
11630
National Ranking
448

Overview

Sonja Zweegman is affiliated with Amsterdam UMC in the Netherlands and focuses their research primarily within the field of medicine. Their work extensively covers several subfields including hematology, oncology, molecular biology, immunology, and genetics. The principal topics explored in their research are multiple myeloma research and treatments, protein degradation and inhibitors, CAR-T cell therapy research, peptidase inhibition and analysis, cancer treatment and pharmacology, myeloproliferative neoplasms, and monoclonal and polyclonal antibodies research.

Zweegman has contributed to multiple publications, frequently appearing in journals such as Blood, HemaSphere, Clinical Lymphoma Myeloma & Leukemia, Leukemia, and The Lancet Oncology. Their research collaboration network includes frequent coauthors like Niels W.C.J. van de Donk, Pieter Sonneveld, Philippe Moreau, Thierry Façon, and Annemiek Broijl.

Notable recent papers authored or coauthored by Zweegman include:

  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, 2020, The Lancet Haematology
  • Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project, 2022, Journal of Clinical Oncology
  • Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial, 2021, The Lancet Oncology
  • Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group, 2021, The Lancet Oncology

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

    Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari

  • Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

    Philippe Moreau;Michel Attal;Cyrille Hulin;Bertrand Arnulf

  • Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos

  • Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca

  • The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells

    Anna Van Rhenen;Guus A.M.S. Van Dongen;Angè Le Kelder;Elwin J. Rombouts

  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

    M A Dimopoulos;P Moreau;E Terpos;M V Mateos

  • High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.

    Anna van Rhenen;Nicole Feller;Angèle Kelder;August H. Westra

  • Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

    Robyn M. Emanuel;Amylou C. Dueck;Holly L. Geyer;Jean Jacques Kiladjian

  • Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    Michele Cavo;Evangelos Terpos;Cristina Nanni;Philippe Moreau

  • Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

    Antonio Palumbo;Sara Bringhen;Heinz Ludwig;Meletios A. Dimopoulos

  • Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

    Annemiek Broyl;Dirk Hose;Henk Lokhorst;Yvonne de Knegt

  • CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

    Inger S. Nijhof;Inger S. Nijhof;Tineke Casneuf;Jeroen van Velzen;Berris van Kessel

  • Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

    Meletios A. Dimopoulos;Jens Hillengass;Saad Usmani;Elena Zamagni

  • European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

    Evangelos Terpos;Martina Kleber;Monika Engelhardt;Sonja Zweegman

  • A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

    Henk M. Lokhorst;Bronno van der Holt;Sonja Zweegman;Edo Vellenga

  • Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study

    Pierre Wijermans;Martijn Schaafsma;Fabian Termorshuizen;Rianne Ammerlaan

  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

    Michele Cavo;Meral Beksac;Lucia Pantani

  • Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

    Claire N. Harrison;Nicolaas Schaap;Alessandro M. Vannucchi;Jean Jacques Kiladjian

  • Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

    Antonio Palumbo;Sara Bringhen;Shaji K Kumar;Giulia Lupparelli

Frequent Co-Authors

Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Michele Cavo
Michele Cavo University of Bologna
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Roman Hájek
Roman Hájek University of Ostrava
Mario Boccadoro
Mario Boccadoro University of Turin
Tuna Mutis
Tuna Mutis Vrije Universiteit Amsterdam
Anders Waage
Anders Waage Norwegian University of Science and Technology
Heinz Ludwig
Heinz Ludwig University of Vienna
Antonio Palumbo
Antonio Palumbo University of Turin
Claire N. Harrison
Claire N. Harrison Guy's and St Thomas' NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always require attending traditional, on-campus programs. Many students today seek flexible options that fit their lifestyle and financial needs. Online degrees now offer diverse pathways into healthcare, opening doors to specialized fields beyond the typical MD route.

For those interested in healthcare leadership, affordable mha online programs provide an excellent foundation. These degrees prepare graduates for management roles in hospitals, clinics, and public health organizations.

If advanced nursing is your passion, consider dnp online programs cheap. Earning a Doctor of Nursing Practice online can help you take on leadership, clinical, or policy-making positions while balancing current work and family obligations.

Aspiring pharmacists can benefit from accredited programs like pharmacy school online accredited. These options ensure you receive a recognized education essential for licensure and future employment.

Lastly, technology-focused students should explore online mhi degrees. Managing health information is a fast-growing field bridging IT and healthcare, ideal for those interested in both industries.

Best Scientists Citing Sonja Zweegman

Trending Scientists

Recently Published Articles